
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 12 |
| Herbal medicine | 5 |
| Polysaccharide | 2 |
| Chemical drugs | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date23 Aug 2018 |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Feb 2026 |
Sponsor / Collaborator |
Start Date01 Feb 2026 |
Sponsor / Collaborator |
Start Date16 Dec 2025 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Basil Capsule | Hepatocellular Carcinoma More | Phase 2 |
Chaiguijiegan Granules | Acute upper respiratory infection More | IND Approval |
2′,4′-Dimethoxychalcone | Inflammation More | Preclinical |
Conpound 13(Shandong Normal University) | Neurodegenerative Diseases More | Preclinical |
Compound 29a(Shandong College of Traditional Chinese Medicine) ( THR ) | Metabolic Dysfunction Associated Steatohepatitis More | Preclinical |





